Trials / Completed
CompletedNCT02941549
Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD
A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Afimmune · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered Epeleuton capsules versus placebo in the treatment of adult patients with Non Alcoholic Fatty Liver Disease (NAFLD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo capsules | |
| DRUG | Epeleuton |
Timeline
- Start date
- 2016-12-20
- Primary completion
- 2019-01-02
- Completion
- 2019-03-04
- First posted
- 2016-10-21
- Last updated
- 2022-10-12
- Results posted
- 2022-04-21
Locations
16 sites across 3 countries: Georgia, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT02941549. Inclusion in this directory is not an endorsement.